Ranatuerin-2PLx, R2PLx

General Information


DRACP ID  DRACP03748

Peptide Name   Ranatuerin-2PLx, R2PLx

Sequence  GIMDTVKNAAKNLAGQLLDKLKCKITAC

Sequence Length  28

UniProt ID  A0A3P8MS06 

PubChem CID  Not available

Origin  Animalia

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C127H226N36O38S3

Absent amino acids  EFHPRSWY

Common amino acids  K

Mass  344342

Pl  9.55

Basic residues  5

Acidic residues  2

Hydrophobic residues  11

Net charge  3

Boman Index  -2156

Hydrophobicity  11.79

Aliphatic Index  108.21

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  125

Absorbance 280nm  4.63

Polar residues  8

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30279210

Title  A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells

Doi Not available

Year  2018

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  12184

DRACP is developed by Dr.Zheng's team.